Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study

Grants

Funding Acknowledgements

The following people participated in this study: Atul Beniwal, Geert Bosma, Joanne Cassar, Therese Dahl, Constanza Daigre, Romain Debrabant, Louisa Degenhardt, Rutger-Jan van der Gaag, David Hay, Kari Lossius, Eva Karin LOvaas, Marion Malivert, Merete Moller, Carlos Roncero, Laura Stevens, Sara Wallhed, Anneke van Wamel and Jesse Young. The authors would like to thank all patients who participated in the IASP study. In the period of development of the study, the ICASA network received unrestricted grants from the following pharmaceutical companies: Janssen Cilag, Eli Lilly & Company and Shire. Since becoming a formal foundation (September 2010), the ICASA network has operated independently from pharmaceutical funding, obtaining funding via the following sources. Participating institutes: the Noaber Foundation, the Waterloo Foundation and the Augeo Foundation. The local institutes report the following funding sources. The Netherlands, Amsterdam: no external funding was obtained. The participating institute, Arkin, paid for the costs involved, and used funding from Fonds NutsOhra for this project. Norway, Bergen Clinics Foundation: main external funding has been the regional research council for addiction in West Norway [Regionalt kompetansesenter for rusmiddelforskning i Helse Vest (KORFOR)], funding a 50% position. The remaining resources, including staff and infrastructure, have been from the Bergen Clinics Foundation. Norway, Fredrikstad: the IASP was funded by the hospital, Sykehuset Ostfold HF not with money, but with 50% of the salary of the participating professionals, then by two sources outside the hospital: the Regional Centre of Dual Diagnosis and the Social and Health directory. Sweden, Stockholm: the study was funded by the Stockholm Centre for Dependency Disorders. Belgium: the IASP project in Belgium received private funding. France, Bordeaux: financial support was received from two funding sources: a Research Grant PHRC (2006-12) from the French Ministry of Health to M.A. and a French National Research Agency PRA-CNRS-CHU-Bordeaux award (2008-10) to M.F. Spain, Barcelona: financial support was received from Plan Nacional sobre Drogas, Ministerio de Sanidad y Politica Social (PND 0080/2011), the Agencia de Salut Publica de Barcelona and the Departament de Salut, Government of Catalonia, Spain. Switzerland, Berne/Zurich: the IASP in Switzerland was funded by the Swiss Foundation of Alcohol Research (grant no. 209). Hungary, Budapest: there was no direct funding, but the following grant was used: the European Union and the European Social Fund have provided financial support to the project under the grant agreement no. TaMOP 4.2.1./B-09/1/KMR-2010-0003. Australia: the IASP Screening Phase was funded by a strategic funding faculty grant from the Curtin University of Technology, Perth, Western Australia. Syracuse, USA: no funding was obtained.